Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mitomycin-c + tegafur-uracil
- Development stage
- Unknown
- Lead developer
- Kyowa Kirin
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Mitomycin-c + tegafur-uracil is a combination chemotherapy regimen used primarily in the treatment of gastrointestinal cancers such as rectal and gastric cancer. Mitomycin C is an antitumor antibiotic that acts as an alkylating agent, cross-linking DNA and inhibiting DNA synthesis. Tegafur-uracil (UFT) is an oral combination of the prodrug tegafur (a masked form of 5-fluorouracil) and uracil; uracil inhibits dihydropyrimidine dehydrogenase, thereby increasing 5-FU levels and enhancing its antitumor effect. This combination exploits synergistic cytotoxicity against tumor cells by combining two distinct mechanisms—DNA crosslinking from mitomycin C and inhibition of thymidylate synthase via 5-FU generated from tegafur[1][2][5]. The regimen has been studied for adjuvant therapy after curative resection in rectal cancer to reduce recurrence rates[5], as well as for advanced gastric cancer[1] and salvage therapy in metastatic colorectal cancer[3].
- Other names
- mitomycin C + UFTMMC + UFTMMC + tegafur-uracil
02
Targets
DPYD (Dihydropyrimidine dehydrogenase)DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on mitomycin-c + tegafur-uracil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mitomycin-c + tegafur-uracil.